Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2016 Feb 4;22(7):1547–1549. doi: 10.1158/1078-0432.CCR-15-3106

Figure 1.

Figure 1

Figure 1

Ibrutinib arrests the chronic inflammatory drive supporting CLL. Within the lymph node, the bi-directional interactions between the CLL cell and inflammatory immune populations (e.g. macrophages, PD1+ T cells, Th17 cells) aid and abet CLL maintenance and expansion (top). Ibrutinib revokes the inflammatory milieu, normalizing immune activation states and exiling CLL from the lymph node (bottom). Image courtesy of Steven Moskowitz.